Acute Lymphocytic Leukemia Clinical Trials
Here is the most popular medical study for acute lymphocytic leukemia
Turalio for Plexiform Neurofibroma
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
Acute Lymphocytic Leukemia Clinical Trials With No Placebo
View 9 acute lymphocytic leukemia medical studies that do not have a placebo group.
CAR T-cell Therapy
JCAR017 + Fludarabine + Lymphodepleting + Cyclophosphamide for B-Cell Lymphoma and Lymphoblastic Leukemia
This trial is testing a new drug to see if it is safe and effective in treating pediatric leukemia and lymphoma. The first part of the trial will test different doses to see what is safe. The second part will test how well the drug works in treating the disease.
Frequently Asked Questions
Introduction to acute lymphocytic leukemia
What are the top hospitals conducting acute lymphocytic leukemia research?
In the battle against acute lymphocytic leukemia (ALL), several top hospitals across the United States have emerged as beacons of hope and progress. The Montefiore Medical Center in Bronx, New York, has been actively involved in two ongoing clinical trials for ALL, adding to their remarkable portfolio of 11 completed studies since their first trial back in 2003. Meanwhile, the M D Anderson Cancer Center located in Houston is also at the forefront with two ongoing trials and an impressive history of 74 previous ALL trials that began in 2000. Not to be outshined, the Memorial Sloan Kettering Cancer Center in New York City has undertaken two current ALL trials and conducted a noteworthy total of 66 studies since initiating their research efforts on this disease from 2005.
Additionally contributing to these advancements are institutions like the University of Miami in Florida, which currently holds one active trial for acute lymphocytic leukemia while having previously executed twelve such investigations starting from as early as 2006. And lastly but by no means least, Wake Forest University Health Sciences situated Winston-Salem stands beside them offering its contribution through one existing clinical test along with forty-one accomplished ones; their journey started all way back until year2--002
These renowned medical centers represent not only cutting-edge research but also compassionate care for those battling acute lymphocytic leukemia. Their commitment to finding novel treatments and potential cures fuels optimism among patients and professionals alike. As each hospital strives towards breakthroughs within this challenging field, they bring us closer to brighter outcomes for individuals affected by this form of leukemia worldwide.
Which are the best cities for acute lymphocytic leukemia clinical trials?
When it comes to acute lymphocytic leukemia clinical trials, several cities emerge as top contenders for cutting-edge research and advancements. Houston, Texas leads the pack with 7 active trials focusing on JCAR017, Dose Escalation: CD19 CAR T Cells for B-cell ALL, Leukemia CNS1 or 2, among others. Dallas, Texas follows closely behind with 3 ongoing studies centered around JCAR017 and Phase 1 Dose Escalation Arm A in patients with R/R Solid Tumors and Lymphomas. New York, Texas leads the pack with 7 active trials focusing on JCAR017, Dose Escalation: CD19 CAR T Cells for B-cell ALL, Leukemia CNS1 or 2, among others. Dallas, Texas follows closely behind with 3 ongoing studies centered around JCAR017 and Phase 1 Dose Escalation Arm A in patients with R/R Solid Tumors and Lymphomas. New York City and Boston both have 3 active trials each exploring various treatments such as Inotuzumab Ozogamicin alongside other interventions. Lastly, the Bronx also contributes to the field with 2 active trials investigating Phase 1 Dose Escalation Arm A in patients with R/R Solid Tumors and Lymphomas among other treatments. These cities serve as pivotal hubs for individuals seeking participation in groundbreaking acute lymphocytic leukemia clinical trials that hold promise for improved care outcomes.
Which are the top treatments for acute lymphocytic leukemia being explored in clinical trials?
Clinical trials are actively exploring promising treatments for acute lymphocytic leukemia (ALL), aiming to improve outcomes for patients. Inotuzumab ozogamicin, a drug first listed in 2011, is currently being investigated in two active trials and has been involved in a total of 19 ALL trials. Another intriguing approach under investigation is mindfulness meditation (MM). Although it's still early stages with just one active trial and one all-time trial since its introduction in 2023, MM shows potential as an alternative therapy for ALL. These ongoing studies offer hope for the future of ALL treatment and may open new doors towards better patient care.
What are the most recent clinical trials for acute lymphocytic leukemia?
Promising advancements have been made in the field of acute lymphocytic leukemia, with recent clinical trials offering hope for patients. Notably, a Phase 4 trial examining the effectiveness of meropenem arm showcased encouraging results in treating this aggressive form of leukemia. Additionally, a Phase 2 study focused on Leukemia CNS1 or 2 has shown potential benefits in managing acute lymphocytic leukemia. Another noteworthy development is a Phase 1 trial investigating Dose Escalation Arm A for relapsed or refractory solid tumors and lymphomas that also holds promise for acute lymphocytic leukemia patients. These latest trials demonstrate significant progress towards improving treatment options and outcomes for those affected by this challenging disease.
What acute lymphocytic leukemia clinical trials were recently completed?
Recent advancements in the field of acute lymphocytic leukemia have seen several clinical trials reach completion, bringing hope for improved treatments. Notably, Amgen concluded a trial investigating Blinatumomab in October 2020, while Children's Mercy Hospital Kansas City completed a study on Daunorubicin in May 2020. Additionally, TCR2 Therapeutics finalized their TC-110 T Cells trial in March 2020. These milestones mark significant progress and demonstrate the commitment of researchers and medical institutions to combat this challenging disease.